What is it about?
This article reviews the epidemiology and the clinical evidence regarding achieving blood pressure (BP) and blood glucose control in patients with chronic kidney disease (CKD) and diabetes mellitus (DM), with emphasis on adherence and barriers within the context of Australian clinical guidelines.
Featured Image
Why is it important?
Our review of the literature, shows that there have been no Australian studies that consider adherence to blood pressure control in DM and CKD patients. This is a major limitation in preventing DM and renal disease progression. It is possible that Australian clinicians are not adhering to DM, hypertension (HT), and glucose recommendations, thus resulting in reduced patient outcomes.
Perspectives
Subsequent studies have now ascertained the extent to which the required BP and glucose control in patients has been achieved, and the potential barriers to adherence. The significance of this is immense since the impact of failure to control blood glucose levels and BP leads to renal damage. By understanding the barriers to control, targeted interventions, with the aim of improving patient outcomes, can now be developed.
Fergus Gardiner
Royal Flying Doctor Service
Read the Original
This page is a summary of: Blood glucose and pressure controls in diabetic kidney disease: Narrative review of adherence, barriers and evidence of achievement, Journal of Diabetes and its Complications, January 2018, Elsevier,
DOI: 10.1016/j.jdiacomp.2017.09.008.
You can read the full text:
Contributors
The following have contributed to this page
